Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings
Guardado en:
| Publicado en: | Molecular Imaging and Radionuclide Therapy vol. 34, no. 1 (Feb 2025), p. 31 |
|---|---|
| Autor principal: | |
| Otros Autores: | , , , , , , , , |
| Publicado: |
Galenos Publishing House
|
| Materias: | |
| Acceso en línea: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3198797654 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2146-1414 | ||
| 022 | |a 2147-1959 | ||
| 024 | 7 | |a 10.4274/mirt.galenos.2024.50470 |2 doi | |
| 035 | |a 3198797654 | ||
| 045 | 2 | |b d20250201 |b d20250228 | |
| 084 | |a 182640 |2 nlm | ||
| 100 | 1 | |a Selçuk, Nalan Alan | |
| 245 | 1 | |a Impact of <sup>68</sup>Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal <sup>18</sup>F-FDG PET/CT Findings | |
| 260 | |b Galenos Publishing House |c Feb 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a ObjectivesThis study aimed to evaluate the potential efficacy of 68Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are 18F-fluorodeoxyglucose (18F-FDG) negative or show equivocal 18F-FDG uptake.MethodsWe conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent 68Ga-FAPi PET/CT and 18F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of 68Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of 18F-FDG PET/CT.Results68Ga-FAPi PET/CT imaging was performed in 30 patients with 18F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on 68Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on 68Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after 68Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on 18F-FDG PET/CT.ConclusionBased on our study, 68Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal 18F-FDG PET/CT findings. 68Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low 18F-FDG -avidity. | |
| 653 | |a Cancer | ||
| 653 | |a Tomography | ||
| 653 | |a Metastasis | ||
| 653 | |a Digestive system | ||
| 653 | |a Medical imaging | ||
| 653 | |a Lesions | ||
| 653 | |a Tumors | ||
| 653 | |a Fibroblast activation protein | ||
| 653 | |a Chromatography | ||
| 653 | |a Metastases | ||
| 653 | |a Positron emission tomography | ||
| 653 | |a Carcinoma | ||
| 653 | |a Statistical analysis | ||
| 653 | |a Patients | ||
| 653 | |a Fibroblasts | ||
| 653 | |a Computed tomography | ||
| 653 | |a Magnetic resonance imaging | ||
| 653 | |a Lymphatic system | ||
| 653 | |a Positron emission | ||
| 653 | |a Fluorine isotopes | ||
| 653 | |a Effectiveness | ||
| 653 | |a Biomarkers | ||
| 653 | |a Colorectal carcinoma | ||
| 653 | |a Gastric cancer | ||
| 653 | |a Lymph nodes | ||
| 653 | |a Malignancy | ||
| 653 | |a Avidity | ||
| 653 | |a Gastrointestinal diseases | ||
| 700 | 1 | |a Beydağı, Gamze | |
| 700 | 1 | |a Akçay, Kaan | |
| 700 | 1 | |a Demirci, Emre | |
| 700 | 1 | |a Görmez, Ayşegül | |
| 700 | 1 | |a Bala, Başak Öven | |
| 700 | 1 | |a Çelik, Serkan | |
| 700 | 1 | |a Şen, Fatma | |
| 700 | 1 | |a Kapar, Özge | |
| 700 | 1 | |a Kabasakal, Levent | |
| 773 | 0 | |t Molecular Imaging and Radionuclide Therapy |g vol. 34, no. 1 (Feb 2025), p. 31 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3198797654/abstract/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3198797654/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3198797654/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch |